LXRX supply chain intelligence for Lexicon Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Lexicon Pharmaceuticals, Inc. (LXRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HTGC | Hercules Capital, Inc. | 92% | Lexicon Pharmaceuticals, Inc. has entered into a loan facility with Hercules Capital, Inc. |
| HTGC | Hercules Capital, Inc. | 92% | Reciprocal relationship from HTGC graph: Reciprocal relationship from LXRX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from LXRX graph: Reciprocal relationship from HTGC g… |
| ARTAL-PARTICIPATIONS-S-R-L | ARTAL-PARTICIPATIONS-S-R-L | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-ADVISORS-L-L-C | INVUS-ADVISORS-L-L-C | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-ENTITIES | INVUS-ENTITIES | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-GLOBAL-MANAGEMENT-LLC | INVUS-GLOBAL-MANAGEMENT-LLC | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-L-P | INVUS-L-P | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-PUBLIC-EQUITIES-ADVISORS-LLC | INVUS-PUBLIC-EQUITIES-ADVISORS-LLC | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-PUBLIC-EQUITIES-L-P | INVUS-PUBLIC-EQUITIES-L-P | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| INVUS-US-PARTNERS-LLC | INVUS-US-PARTNERS-LLC | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| NOVO-NORDISK | NOVO-NORDISK | 90% | LX9851 is a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) in development by Novo Nordisk for obesity and associated metabolic disorders |
| OXFORD-FINANCE | OXFORD-FINANCE | 90% | The initial $55 million tranche was funded at closing and will be used to repay Lexicon’s existing loan facility with Oxford Finance. |
| PREFERRED-PRIVATE-PLACEMENT-PURCHASER | PREFERRED-PRIVATE-PLACEMENT-PURCHASER | 90% | Additionally, on January 29, 2026, the Company entered into a Preferred Stock Purchase Agreement with an affiliate of Invus (the “ Preferred Private Placement Purchaser ” and, such agreement, the “ P… |
| RAYMOND-DEBBANE | RAYMOND-DEBBANE | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| SIREN-LLC | SIREN-LLC | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| ULYS-L-L-C | ULYS-L-L-C | 90% | On February 2, 2026, pursuant to the Common Stock Purchase Agreement and concurrently with the closing of the Public Offering, affiliates of Invus (the “ Private Placement Purchasers ”) purchased 22,… |
| OXFORD-TERM-LOANS | OXFORD-TERM-LOANS | 80% | As of March 31, 2026, we are subject to interest rate sensitivity on our outstanding Oxford Term Loans which bear interest at a floating rate equal to the 1-month CME Term SOFR rate. |
| STENO-DIABETES-CENTER | STENO-DIABETES-CENTER | 80% | STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark) |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NVO | Novo Nordisk A/S | 95% | Reciprocal relationship from NVO graph: Reciprocal relationship from LXRX graph: In March 2025, we entered into an exclusive license agreement with Novo Nordisk A/S for the worldwide development, man… |
| NVO | Novo Nordisk A/S | 95% | . In March 2025, the Company entered into an exclusive license agreement (the “Novo Nordisk License Agreement”) with Novo Nordisk A/S (“Novo Nordisk”) for the worldwide development, manufacturing and… |
| NOVO-NORDISK | NOVO-NORDISK | 92% | Lexicon earned a second $10 million milestone payment in 2026 from Novo Nordisk in connection with initiation of the Phase 1 study |
| NOVO-NORDISK-A-S | NOVO-NORDISK-A-S | 92% | In March 2025, we entered into an exclusive license agreement with Novo Nordisk A/S for the worldwide development, manufacture and commercialization of LX9851, our preclinical drug candidate for obes… |
| VIATRIS-INC | VIATRIS-INC | 92% | In October 2024, we entered into an exclusive license agreement with Viatris Inc. for the development and commercialization of sotagliflozin in all markets outside of the United States and Europe, pu… |
| BMY | Bristol-Myers Squibb Company | 90% | Reciprocal relationship from BMY graph: Reciprocal relationship from LXRX graph: Under our drug discovery alliance with Bristol-Myers Squibb, we will be required to make a milestone payment of $5 mil… |
| BMY | Bristol-Myers Squibb Company | 90% | Under our drug discovery alliance with Bristol-Myers Squibb, we will be required to make a milestone payment of $5 million upon dosing of the first patient in a Phase 3 clinical trial of pilavapadin. |
| VIATRIS | VIATRIS | 90% | Lexicon continues to support licensee Viatris in its regulatory filing and commercial strategy for sotagliflozin outside of the U.S. and Europe |
| RAPP | Rapport Therapeutics, Inc. | 72% | Reciprocal relationship from RAPP graph: Reciprocal relationship from LXRX graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from LXRX graph: Reciprocal relationship from RAPP g… |
| F-2-LEXICON-PHARMACEUTICALS-INC | F-2-LEXICON-PHARMACEUTICALS-INC | 62% | Note 2 and Note 5 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials.… |
| F-3-LEXICON-PHARMACEUTICALS-INC | F-3-LEXICON-PHARMACEUTICALS-INC | 62% | Note 2 and Note 5 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials.… |
| F-4-LEXICON-PHARMACEUTICALS-INC | F-4-LEXICON-PHARMACEUTICALS-INC | 62% | Note 2 and Note 5 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials.… |
| F-5-LEXICON-PHARMACEUTICALS-INC | F-5-LEXICON-PHARMACEUTICALS-INC | 62% | Note 2 and Note 5 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials.… |
| F-6-LEXICON-PHARMACEUTICALS-INC | F-6-LEXICON-PHARMACEUTICALS-INC | 62% | Note 2 and Note 5 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials.… |
| OPERATIONS-LEXICON-PHARMACEUTICALS-INC | OPERATIONS-LEXICON-PHARMACEUTICALS-INC | 62% | Note 2 and Note 5 to the consolidated financial statements, the Company records accruals for estimated costs of research and development activities that include contract services for clinical trials.… |
| OXFORD-FINANCE-LLC | OXFORD-FINANCE-LLC | 62% | c or epidemic is highly uncertain and subject to change. These effects could have a material impact on our operations. Changes in government trade policies, including tariffs, sanctions and trade bar… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LXRX-DEBT-10842 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| LXRX-DEBT-10841 | Warrants outstanding: 0 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| LXRX-DEBT | Debt stack $51.4M | 90% | Market cache reports total debt of $51.4M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LXRX-OWNER-ARTAL-GROUP-S-A | Artal Group S.A. | 90% | 13F overlay lists Artal Group S.A. as top holder; 138 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer'] |
| IBIO | iBio, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| EVAX | Evaxion A/S | 100.00 | 2 | |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 | |
| HIMS | Hims & Hers Health, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 1 | ['supplier'] |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer'] |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| JANX | Janux Therapeutics, Inc. | 100.00 | 2 |